drugset / Trial / NCT05284019
Real World Effectiveness of Eptinezumab in Participants With Migraine
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.
Timeline
- Start
- 2022-03-04
- Primary completion
- 2023-02-17
- Completion
- 2023-04-14
Outcome
Outcome not reported
Stopped: “The study was terminated due to enrolment challenges.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | — | Intramuscular |
| Subject | Eptinezumab | Monoclonal antibody | — | Intravenous |
| Subject | Erenumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Fremanezumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | — | Subcutaneous |